

RESEARCH PAPER

The compound BTB06584 is an IF₁-dependent selective inhibitor of the mitochondrial F₁Fo-ATPase

Fabrice Ivanes^{1*†}, Danilo Faccenda², Jemma Gatliff², Ahmed A Ahmed^{1,2}, Stefania Cocco³, Carol Ho Ka Cheng², Emma Allan^{1,2}, Claire Russell², Michael R Duchen¹ and Michelangelo Campanella^{2,3,4}

¹Department of Cell and Developmental Biology, University College London, London, UK,

²Department of Comparative Biomedical Sciences, The Royal Veterinary College, London, UK,

³European Brain Research Institute-Rita Levi-Montalcini Foundation, Rome, Italy, and

⁴Consortium for Mitochondrial Research, University College London, London, UK

Correspondence

Michelangelo Campanella,
Department of Comparative
Biomedical Sciences, The Royal
Veterinary College, Royal College
Street, London NW1 0TU, UK.
E-mail: mcampanella@rvc.ac.uk

Present addresses: *INSERM UMR
1060, CarMeN, Lyon, France.

†Université Lyon I, Faculté de
Médecine Lyon Est, Lyon, France.

Received

7 August 2013

Revised

16 January 2014

Accepted

30 January 2014

BACKGROUND AND PURPOSE

Ischaemia compromises mitochondrial respiration. Consequently, the mitochondrial F₁Fo-ATP synthase reverses and acts as a proton-pumping ATPase, so maintaining the mitochondrial membrane potential ($\Delta\Psi_m$), while accelerating ATP depletion and cell death. Here we have looked for a molecule that can selectively inhibit this activity without affecting ATP synthesis, preserve ATP and delay ischaemic cell death.

EXPERIMENTAL APPROACH

We developed a chemoinformatic screen based on the structure of BMS199264, which is reported to selectively inhibit F₁Fo-ATPase activity and which is cardioprotective. Results suggested the molecule BTB06584 (hereafter referred to as BTB). Fluorescence microscopy was used to study its effects on $\Delta\Psi_m$ and on the rate of ATP consumption following inhibition of respiration in several cell types. The effect of BTB on oxygen (O₂) consumption was explored and protective potential determined using ischaemia/reperfusion assays. We also investigated a potential mechanism of action through its interaction with inhibitor protein of F₁ subunit (IF₁), the endogenous inhibitor of the F₁Fo-ATPase.

KEY RESULTS

BTB inhibited F₁Fo-ATPase activity with no effect on $\Delta\Psi_m$ or O₂ consumption. ATP consumption was decreased following inhibition of respiration, and ischaemic cell death was reduced. BTB efficiency was increased by IF₁ overexpression and reduced by silencing the protein. In addition, BTB rescued defective haemoglobin synthesis in zebrafish *pinotage* (*pnt*) mutants in which expression of the *Atpif1a* gene is lost.

CONCLUSIONS AND IMPLICATIONS

BTB may represent a valuable tool to selectively inhibit mitochondrial F₁Fo-ATPase activity without compromising ATP synthesis and to limit ischaemia-induced injury caused by reversal of the mitochondrial F₁Fo-ATP synthase.

LINKED ARTICLES

This article is part of a recent themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond published in volume 171 issue 8. To view the other articles in this issue visit <http://dx.doi.org/10.1111/bph.2014.171.issue-8>

Abbreviations

ANT, adenine nucleotide translocase; BTB06584, 2-nitro-5-(phenylsulfonyl)phenyl 4-chlorobenzoate; CFP, cyan fluorescent protein; CsA, cyclosporine A; $\Delta\Psi_m$, mitochondrial membrane potential; ETC, electron transport chain; FCCP, carbonyl cyanide p-trifluoromethoxy-phenylhydrazone; FDA, fluorescein diacetate; FLIPR, fluorescent imaging plate reader; IAA, iodo acetic acid; IF₁, inhibitor protein of F₁ subunit; MgG, magnesium green; mPTP, mitochondrial permeability transition pore; OGD, oxygen-glucose deprivation; pnt, pinotage zebrafish; Rh123, rhodamine 123; RX, reoxygenation; TMRM, tetramethylrhodamine methyl ester; YFP, yellow fluorescent protein

Introduction

In eukaryotic cells, ATP is mainly produced through oxidative phosphorylation, which is dependent on the activity of the mitochondrial F₁F₀-ATP synthase. When the oxygen supply is compromised, for example, during ischaemia, the F₁F₀-ATP synthase runs in reverse, acting as an ATPase, hydrolysing ATP and maintaining the proton motive force and thus the mitochondrial membrane potential ($\Delta\Psi_m$) at the expense of the cellular supplies of ATP (Rouslin *et al.*, 1990; Vinogradov, 2000). This ATP consumption, referred to as ATP wastage, makes a significant contribution to cell death (Harris and Das, 1991; Jennings *et al.*, 1991).

The inhibitor protein of F₁ subunit (IF₁) is a small nuclear-encoded endogenous inhibitor of the F₁ domain of the mitochondrial F₁F₀-ATP synthase. First discovered in bovine heart, it is ubiquitously expressed in the body albeit at varying levels, according to the species and the tissue considered (Rouslin, 1991; Green and Grover, 2000). In rare cases, its absence is responsible for a mitochondrial myopathy (Luft *et al.*, 1962). This highly sequence-conserved protein is highly specific for the ATP hydrolase activity, acting as a reversible non-competitive inhibitor. Inhibition of the F₁F₀-ATPase requires an acid pH (~6.7), which promotes binding of the endogenous inhibitor to the enzyme, a condition encountered during ischaemia (Power *et al.*, 1983; Rouslin *et al.*, 1986; Cabezon *et al.*, 2000). IF₁ binding disrupts the connection between the central γ - and β -subunits, inhibiting ATP hydrolase activity of the F₁ complex (Cabezon *et al.*, 2001). Thus, IF₁ may play a significantly protective role in the pathophysiology of ischaemia, as ATP wastage by the F₁F₀-ATPase accounts for a large fraction of ATP consumption, in the rodent cardiomyocyte.

The binding of IF₁ to the F₁ subunit is capable of reducing this wastage by up to 80% (Rouslin *et al.*, 1995). Indeed, overexpression of IF₁ is significantly protective in a hypoxia re-oxygenation cell model (Campanella *et al.*, 2008). A molecule that mimics or potentiates the action of IF₁ could significantly improve the outcome in pathologies associated with impaired oxygen supply. Grover *et al.* (2004) developed such a compound, named BMS199264 (Atwal *et al.*, 2004), which reduced infarct size in the isolated rat heart. However, as no further original publications have confirmed its positive effects, the question remains open: is it possible to find a molecule that can selectively inhibit mitochondrial ATPase activity without also compromising ATP synthesis? Could such a drug be clinically useful? And how could we explain its specificity towards the hydrolase activity of the F₁F₀-ATP synthase?

Following a chemoinformatic screen based on the molecular conformation of the BMS compound, we selected

the molecule BTB06584 (hereafter referred as BTB), which we have tested for its biological efficacy *in vitro* and *in vivo*, characterizing a potential chemical lead to preserve cell integrity during acute pathological conditions (ischaemia) associated with reversal of the F₁F₀-ATP synthase and bio-energetic defects (haemoglobin synthesis) associated with reduction in endogenous IF₁.

Methods

Virtual screening of compounds

We performed the screening for BTB according to the protocol published by Professor Grant Churchill and his collaborators (Naylor *et al.*, 2009; Rosen *et al.*, 2009). In detail, using ZINC, a free database of commercially available compounds for virtual screening, provided by the Shoichet Laboratory in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (Irwin and Shoichet, 2005), we ran a rapid overlay of chemical structures analysis based on shape and colour similarity with BMS scoring molecules between a range value of 0.1 and 1.0 (with the latter bearing greater similarity) and eliminated those characterized by CH₃ groups making these biologically inert. The most robust hit was ZINC01044546, also known as Oprea1_170890, AC1ME324, MolPort-002-891-783, BTB06584, CCG-42771, 2-nitro-5-(phenylsulfonyl)phenyl 4-chlorobenzoate, SR-01000632744-1. Molecular formula: C₁₉H₁₂ClNO₆S, molecular weight: 417.81968, InChIKey: WNDWKKPBLAKXMI-UHFFFAOYSA-N.

Following this, the program <http://autodock.scripps.edu>, a suite of automated docking tools, was used to predict how and where the chosen compound would bind to the F₁F₀-ATP synthase and then generate a three-dimensional structure of the complex.

Cell cultures

HL-1 cells, a cardiac cell line derived from a mouse atrial cardiomyocyte tumour lineage, were cultured according to the instructions from Claycomb *et al.* (1998). HeLa cells, derived from a human cervix cancer lesion, were grown in standard DMEM supplemented with FBS (10%), penicillin (100 U·mL⁻¹), streptomycin (100 μ g·mL⁻¹) and L-glutamine (4 nM). The cells were cultured in DMEM-F12 (Gibco, Life Technologies, Paisley, UK) (10% inactivated FBS and penicillin/streptomycin) at 37°C, 5% CO₂ and 95% air in an incubator for cell culture. FuGENE® 6 transfection reagents (Roche, Penzberg, Upper Bavaria, Germany) were used for the transfection experiments in HL-1 cells. Cells were co-transfected with either cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP) in addition to IF₁ construct

(a gift from Professor Sir John Walker) or IF₁ siRNA (Qiagen, Manchester, UK) to overexpress or silence IF₁ respectively.

Fluorescent imaging plate reader (FLIPR) experiments

To assess the appropriate concentration of BTB required to inhibit the F₁Fo-ATPase, cells were first exposed to rotenone (5 μM), which inhibits complex I of the electron transport chain (ETC), resulting in a reversal of the activity of the F₁Fo-ATP synthase. Subsequently, they were challenged with BTB at several concentrations from 1 to 100 μM – effective inhibition of the ATPase will then cause a loss of ΔΨ_m. The potential was measured using rhodamine 123 (Rh123), a lipophilic cationic fluorescent dye used in ‘quench/dequench’ mode (loaded at 20 μM, for 10 min followed by a wash). At this concentration, when the ΔΨ_m falls, the dye, initially located in the mitochondria, redistributes to the cytosol and its mean fluorescence increases (Duchen *et al.*, 2003).

Fluorescence imaging

All imaging experiments were performed with either a Zeiss 510 CLSM (Carl Zeiss Microscopy GmbH, Jena, Germany) or Leica SP5 confocal microscopes (Leica Microsystems, Wetzlar, Germany), using appropriate lasers and emission filters. ΔΨ_m was assessed using Rh123 or tetramethylrhodamine methyl ester (TMRM). HL-1 cells loaded with Rh123 were imaged intermittently during 18 min using a 488 nm laser with the emission optimally monitored at 530 nm, and the changes in fluorescence were recorded after addition of inhibitors of the ETC (rotenone 5 μM and antimycin A 1 mg·mL⁻¹ for HL-1) followed by addition of either BTB or oligomycin B (3 μM) as a positive control. We found that the best and most sensitive way to explore the changes in ΔΨ_m using Rh123 in quench/dequench mode (10 μg·mL⁻¹) was to calculate the SD of the mean fluorescence ratio. The SD of the signal directly reflects the redistribution of the dye: it is high when the mitochondria are polarized as the dye is located preferentially in the mitochondria. Following mitochondrial depolarization, the fluorescence in the cytosol increases, the fluorescence signal becomes more uniform and thus the SD goes down. It is necessary to correct changes in SD in relation to changes in the mean fluorescence, as the SD will vary with the mean signal. Thus, the SD/mean ratio provides the best sensitivity possible to detect significant changes in ΔΨ_m.

Changes in cellular ATP content were measured using the fluorescent dye, magnesium green (MgG-AM, 5 μM) (Leyssens *et al.*, 1996). MgG fluorescence is a measure of concentration of free [Mg²⁺], which has a strong affinity with ATP, whereas its affinity for ADP is 10-fold less. Therefore, ATP hydrolysis is associated with a rise in free Mg²⁺. All cells were imaged in a ‘normal recording saline’. For the experiments with MgG, glucose was replaced with 2-deoxyglucose to ensure inhibition of glycolytic production of ATP.

In ischaemia/reperfusion experiments, the cell death ratio was calculated after loading the cells with Hoechst (1 μg·mL⁻¹) and propidium iodide (PI, 15 μg·mL⁻¹) and corresponded to the PI-positive/Hoechst-positive ratio.

The mitochondrial network of HeLa cells was monitored via MitoTracker® Green FM (Invitrogen, Life Technologies, Paisley, UK). Briefly, cells were stained with 100 nM MitoTracker Green FM for 45 min at 37°C, 5% CO₂. After

staining, cells were washed twice with normal recording medium, then either directly imaged with a Leica SP5 confocal microscope or incubated with 100 μM BTB for 2 h at 37°C, 5% CO₂ before imaging.

Ischaemia/reperfusion

Ischaemia/reperfusion experiments in HL-1 cells were performed using an airtight gas chamber (Wolf Laboratories, Pocklington, UK) filled with 95% N₂/5% CO₂ after replacing the Claycomb medium (Sigma Aldrich, St. Louis, MO, USA) with an ischaemic medium (in mM: NaCl 125, KCl 8, 2-deoxyglucose 20, Na lactate 0.5, MgSO₄ 1.25, CaCl₂ 1.25, KH₂PO₄ 1.2, NaHCO₃ 6.25, HEPES 20; pH 7.4). The chamber was stored for 7 h in an incubator at 37°C. Reperfusion consisted of replacing the ischaemic medium with an oxygenated reperfusion medium (as described above but modified to: NaHCO₃ 25mM, CaCl₂ 1mM, HEPES 10mM; pH 7.4) and storing the culture plates for 1 h in a normoxic incubator. Five experimental groups were considered: sham, control (ischaemia/reperfusion without any intervention), cyclosporine A (CsA) 200 nM a potent inhibitor of the mitochondrial permeability transition pore (mPTP), diazoxide 10 μM, a mitochondrial K-ATP channel opener, and BTB 100 μM.

Cortical neuronal preparation, combined oxygen and glucose deprivation (OGD) plus reoxygenation (RX) and intravital staining

Procedures involving animals and their care were conducted in strict accordance with the Policy on Ethics approved by the Society for Neuroscience and with the European Communities Council Directive for Experimental Procedures. Every effort was made to minimize the number of animals used and any possible suffering caused to them. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010). A total of 3 mice and 75 zebrafish embryos were used in the experiments described here.

Cortical neurons were isolated from 15-day-old C57BL/6N mouse embryos according to Dugan *et al.* (1995) and cultured as described in Carunchio *et al.* (2007). Cortical neurons were exposed to OGD for 3 h followed by 24 h RX (Goldberg and Choi, 1993). Briefly, the culture medium was replaced with a hypoxia medium previously saturated for 20 min with 95% N₂ and 5% CO₂ and containing NaCl 116 mM, KCl 5.4 mM, MgSO₄ 0.8 mM, NaHCO₃ 26.2 mM, NaH₂PO₄ 1 mM, CaCl₂ 1.8 mM, glycine 0.01 mM and 0.001 w/v phenol red. Hypoxic conditions were maintained using a hypoxia chamber (temperature 37°C, atmosphere 95% N₂ and 5% CO₂). These experimental conditions induced 30% decrease of P_{O₂} in the medium. Deprivation of oxygen and glucose was stopped by placing the cells in the usual culture medium, saturated with a mixture of 95% O₂ and 5% CO₂ for 10 min. Reoxygenation was achieved by returning neurons to normoxic conditions (37°C in a humidified 5% CO₂ atmosphere) for 24 h (Savoia *et al.*, 2011). BTB 100 μM was added during the 3 h of OGD.

After the experimental procedure, cortical neurons were washed with the standard medium and stained for 3 min at 22°C with a solution containing 36 μM fluorescein diacetate (FDA) (Sigma Aldrich) and 7 μM PI (Calbiochem, San Diego,

CA, USA). The stained cells were examined immediately with a confocal laser-scanning microscope (Leica SP5). FDA, a non-polar ester, crosses the cell membrane and is hydrolysed by intracellular esterases to produce a green-yellow fluorescence. Cell injury curtails FDA staining and allows for cell permeation with PI, a polar compound that, by interacting with nuclear DNA, yields a bright red fluorescence (Manev *et al.*, 1990).

Immunofluorescence assay

Successful overexpression or silencing of IF₁ was demonstrated by immunofluorescence experiments. We used a rabbit polyclonal anti-mouse ATP1F1 antibody (ProteinTech Europe, Manchester, UK) (1/100) in conjunction with an anti-rabbit Cy3 antibody (1/50). Cells were fixed with paraformaldehyde 4% and stored at 4°C before imaging.

Gel electrophoresis and immunoblot analyses

Sample proteins were quantified using a BCA protein assay kit (Thermo Scientific, Loughborough, UK). Equal amounts of protein (20 µg) were resolved in kD TGX™ (Bio-Rad Laboratories, Hemel Hempstead, UK), 15% polyacrylamide gels and transferred to nitrocellulose membrane. The membrane was blocked in 2% non-fat dry milk in TBST [50 mM Tris, 150 mM NaCl, 0.05% Tween 20 (Sigma Aldrich), pH 7.5] for 1 h then incubated with the appropriate diluted primary antibody at 4°C overnight: mouse α -ATP1F1 (clone 5E2D7) (Abcam, Cambridge, UK) 1:1000 or α -GAPDH:Hrp conjugated (Abcam) 1:20 000. The membrane was washed in TBST (3 × 15 min at room temperature) and then incubated with corresponding peroxidase-conjugated secondary antibodies for 1 h at room temperature. After further washing in TBST, the blot was developed using an ECL Plus Western blotting detection kit (Amersham, GE Healthcare Life Sciences, Little Chalfont, UK). Immunoreactive bands were analysed by performing densitometry with ImageJ software (NIH, Bethesda, MD, USA).

Oxygen consumption experiments

HL-1 cells were trypsinized and suspended in normal recording medium at a concentration of $10 \times 10^6 \cdot \text{mL}^{-1}$. Non-permeabilized cells (1×10^6) were placed in a chamber in contact with a Clark electrode (Hansatech Instruments, Norfolk, UK), and oxygen tension was continuously monitored in basal conditions and after addition of either BTB, oligomycin B or carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) to determine a possible inhibiting effect on the ATP synthase or an inhibition of respiration that might limit the uncoupling induced maximal oxygen consumption.

Zebrafish experiments

Ethical approval for zebrafish experiments was obtained from the Royal Veterinary College and the Home Office (UK) under the Animal (Scientific Procedures) Act 1986. *pnt*^{tg209} carrier zebrafish (Shah *et al.*, 2012) were obtained from the Tübingen Stock Center. Zebrafish were housed in a multi-rack aquarium system at the Royal Veterinary College and kept on a constant 14/10 h light/dark cycle at 27–29°C, bred and staged as described (Westerfield, 2007). BTB (0.1 mM in DMSO) and DMSO alone as control, were diluted to a final concentration of 1 µM in aquarium water and added to embryos from a *pnt*

heterozygous cross at 1 day post fertilization (dpf). This BTB concentration was chosen as it did not induce any toxicity on the animal, as was reported with greater concentrations. At 3 dpf, larvae were examined under a Nikon SMZ1500 microscope (Nikon, Kingston upon Thames, UK) and scored as having red or clear blood. The experiment was repeated four times. Images were taken using a Digital Sight DS-2 Mv camera (Nikon) and associated Digital Sight imaging software (Nikon).

Measuring $\Delta\Psi_m$ and haemoglobin in zebrafish larvae

WT and *pnt* embryos were separated at 3 dpf and either treated with a vehicle (DMSO) or 1 µM BTB diluted in PBS for 1.5 h for TMRM and 3 h for o-dianisidine at 28°C.

For $\Delta\Psi_m$, larvae were simultaneously exposed to the cell-permeant, cationic red fluorescent dye TMRM (300 nM) that is sequestered by polarized mitochondria. After incubation, embryos were washed twice in PBS before mounting in 2% low melting point agarose gel in PBS onto a glass-bottomed culture dish. Z-stack images were taken using a 40X objective with a Leica SP5 confocal microscope. Microscope parameters including gain, offset, z-stack slice number and laser power were kept constant between experiments. The olfactory bulb of each embryo was selected for imaging as this region exhibited consistent TMRM loading, permitting comparison between conditions. Ten mitochondrial regions of interest were demarcated in the olfactory bulb per embryo, and the mean maximum fluorescence intensity was calculated from this.

For o-dianisidine staining after BTB treatment, larvae were washed in PBS then stained for 15 min in the dark in o-dianisidine ($0.6 \text{ mg} \cdot \text{mL}^{-1}$) (Paffett-Lugassy and Zon, 2005), 0.01 M sodium acetate (pH 4.5), 0.65% H₂O₂ and 40% (v/v) ethanol. The stained larvae were washed once in PBS prior to fixing in 4% PFA overnight at 4°C. After fixation, larvae were washed in PBS again before placing in 70% glycerol/PBS solution where they were equilibrated for at least 1 h before imaging on a Nikon SMZ1500 microscope using a Digital Sight DS-2 Mv camera and associated Digital Sight imaging software.

Measurement of mitochondrial matrix pH

Mitochondrial matrix pH was assessed using the cell-permeant pH indicator probe 5-(and-6)-carboxy SNARF@-1 AM acetate (Molecular Probes®, Invitrogen) as reported previously in Shah *et al.* (2012). HeLa cells were seeded on Ø22 mm borosilicate coverslips and, following overnight growth at 37°C, 5% CO₂, co-loaded with 10 µM carboxy SNARF-1 AM acetate and 200 nM MitoTracker Green FM in recording medium (30 min incubation at 37°C, 5% CO₂). After 30 min incubation, the dye was removed and cells were incubated in recording medium for 2.5 h to allow the hydrolysis of cytosolic carboxy SNARF-1 AM acetate and the preferential compartmentalization of the probe into the mitochondria. Cells were imaged using a 'Fluar' 40×/1.30 oil immersion objective; to avoid contamination between carboxy SNARF-1 AM acetate and MitoTracker Green FM emissions, a sequence of three consecutive scans was performed throughout, using a green helium–neon laser (543 nm line) for the former and an argon laser (488 nm line) for the latter. Fluorescence emission of carboxy SNARF-1 AM acetate at 590 and 680 nm was captured in two consecutive scans through the HTF 488/543 dichroic mirror with BP 565/

615 band pass filter and LP 650 high pass filter, while MitoTracker Green FM, whose staining was used to select only mitochondrial pixels and derive the mitochondrial calibration curve avoiding contaminations from cytosolic signal, through the HTF 488/543 dichroic mirror with BP 510/520 band pass filter. *In situ* pH calibration of carboxy SNARF-1 AM acetate was performed using control DMSO-treated cells; cells were exposed to high-K⁺ buffer supplemented with 13 mM nigericin, 1 μ M FCCP and 20 μ g·mL⁻¹ oligomycin to achieve equilibration of the external and internal pH and of cytosolic and mitochondrial matrix pH through permeabilization of plasma membrane and mitochondrial membrane in conjunction with suppression of the F₁Fo-ATP synthase activity. The pH of the solution was set to four different values (6.0, 7.0, 8.0 and 9.0), and the calibration was performed both from low to high pH and vice versa. Averaged SNARF-1 AM acetate ratios (680/590 nm) were plotted against pH values to build up the calibration curve and measure mitochondrial matrix pH_m (maintaining the same settings, chosen to minimizing bleaching). Basal pH_m measurements of treatment were performed in recording medium, and emission intensities were quantified with the LSM Image Browser software (Carl Zeiss Microscopy GmbH).

Data analysis

Confocal images were processed using the FIJI software (Schindelin *et al.*, 2012). Data are expressed as means \pm SEM. Statistical analysis was performed using the GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). We used one-way ANOVA with either Dunnett's or Newman-Keuls's multiple comparison test as a post-test where necessary. For zebrafish data, the chi-square test was employed for prolonged treatments and Student's *t*-test for acute treatments. *P* < 0.05 was considered statistically significant.

Materials

All materials were purchased from Sigma Aldrich unless stated otherwise, and the fluorescent dyes from Molecular Probes (Life Technologies, Paisley, UK). The company Ambinter (Orléans, France) (<http://www.ambinter.com/search-chemical-compounds>) supplied the BTB 06584.

Results

Selection and characterization of BTB06584

From the chemoinformatic screen of molecules potentially sharing the same structural characteristics as BMS199264 (and so with a similar biological activity) using the open database ZINC (<http://zinc.docking.org>), we obtained 10 initial hits without toxic chemical groups within their structure. Among these we then selected ZINC01044546, also known as BTB06584 as the one scoring higher among the others for similarity with the benchmark molecule BMS199264. Figure 1A shows the two-dimensional structure of the molecule. To corroborate this we performed an automated docking analysis to predict the binding sites for the BTB hit. This suggested that the selected molecule might have a significant interactivity with the soluble catalytic core, F₁, of the F₁Fo-ATP synthase (Figure 1B). We have also generated a three-dimensional ribbon reconstruction (Papadimitriou

et al., 2004) of the selected binder (BTB) in complex with the F₁Fo-ATP synthase of which we also present an animated version to better visualize the likely interactivity (Supporting Information Figure S1a,b).

Determination of the optimal working concentrations

A number of BTB concentrations were initially tested on cardiac muscle cell line HL-1, by assessing the effect on $\Delta\Psi_m$ with a FLIPR, using Rh123 in 'dequench mode', whereby an increase in fluorescence reports mitochondrial depolarization. Rotenone (5 μ M) was applied first to the cells to inhibit respiration. In these cells, $\Delta\Psi_m$ is then maintained quite effectively by reversal of the F₁Fo-ATPase, revealed with a mitochondrial depolarization in response to subsequent addition of oligomycin. Thus, BTB was tested using the same paradigm and caused a loss of $\Delta\Psi_m$ at 100 μ M (Figure 1C and D). The effect of BTB was not significantly different from that of oligomycin B (3 μ M) (Matsuno-Yagi and Hatefi, 1993), the inhibitor of the F₁Fo-ATP synthase that was used as a positive control. This experiment was also confirmed by confocal microscopy with identical results (data not shown).

Effects of BTB on 'resting' mitochondrial function

To determine whether, at this concentration (100 μ M), BTB had any direct effects on mitochondrial respiration or F₁Fo-ATP synthase activity, we measured its effect on $\Delta\Psi_m$, without prior addition of an inhibitor of the ETC. In HL-1 cells, BTB did not induce any significant change in $\Delta\Psi_m$ (measured as a change in the ratio of the SD/mean of the fluorescence signal), supporting its selectivity towards the ATP hydrolase, compared with oligomycin B, which, in contrast, increased $\Delta\Psi_m$ as expected, reflecting inhibition of the proton flux through the F₁Fo-ATP synthase (Figure 1E).

Loading a different cell type, HeLa, with the fluorescent dye TMRM, we monitored the $\Delta\Psi_m$ over time and no effect was recorded in the same resting respiratory conditions. In contrast, oligomycin B increased $\Delta\Psi_m$ as expected following inhibition of the F₁Fo-ATP synthase (Supporting Information Figure S1c).

To further establish any direct effect on mitochondrial respiration, we measured O₂ consumption in cell suspensions using a Clark-type electrode (Figure 1F). Addition of oligomycin B reduced O₂ consumption as expected in response to inhibition of the F₁Fo-ATP synthase, whereas addition of the uncoupler FCCP (500 nM) maximized the rate of O₂ consumption. BTB did not induce any significant change compared with basal conditions, nor did it alter maximal oxygen consumption in response to FCCP, supporting its selectivity on the F₁Fo-ATPase.

BTB slows intracellular ATP consumption following inhibition of respiration

The next step was to determine the effects of BTB on rates of ATP depletion during inhibition of respiration. For this, we measured the level of free intracellular Mg²⁺ through the mean fluorescence of the dye MgG, using fluorescence microscopy. The level of free Mg²⁺ in a cell is inversely related to the availability of the unbound ATP, as its affinity to ATP is




Figure 1

BTB chemical structure, ribbon diagram and effect on mitochondrial respiration. (A) Chemical structure of BTB. (B) BTB interaction conformer. (C) Determination of the optimal concentration of BTB in a FLIPR assay run in HL-1 cells by monitoring the $\Delta\Psi_m$ after inhibition of the ETC by rotenone, which leads to the reversal of the ATP synthase. The Y axis shows the mean fluorescence of Rh123 in arbitrary units. In these experimental conditions, an increase in the mean fluorescence reports mitochondrial depolarization. Concentrations of BTB from 1 to 100 μM were tested; only 100 μM of BTB resulted in a significant increase in mean fluorescence in conditions when the ATP synthase is reversed, suggesting the inhibition of the ATP hydrolase activity. $**P < 0.001$, significantly different from control. (D) Snapshot of representative FLIPR recording of rotenone, rotenone + oligomycin and rotenone + BTB. (E) Effect of BTB on $\Delta\Psi_m$ in HL-1 cells loaded with Rh123 assessed by the changes in SD/mean fluorescence ratio in fluorescence microscopy. The bars show the change (normalized) in $\Delta\Psi_m$ 15 min after the addition of BTB or oligomycin. Control, $n = 16$; oligomycin B, $n = 18$; BTB (100 μM), $n = 46$. $**P < 0.001$, significantly different as shown. (F) Effect of BTB on oxygen consumption following addition of the drugs: BTB did not affect the rate of O₂ consumption whereas oligomycin B decreased it (inhibition of synthesis of ATP) and FCCP increased it (uncoupling effect). Control, $n = 6$; oligomycin B, $n = 8$; BTB 100 μM , $n = 10$; FCCP 500 nM, $n = 5$. $**P < 0.001$, $*P < 0.05$, significantly different as shown.

10 times higher than its affinity for ADP. In response to inhibition of respiration using rotenone (5 μ M) and antimycin A (1 μ M), MgG fluorescence rose progressively. BTB (100 μ M) significantly slowed the increase in MgG fluorescence under the same conditions. Similar results were obtained using oligomycin B (Figure 2A).

To further corroborate these data, these experiments were duplicated using HeLa cells. Cells were treated with NaCN and iodoacetic acid (IAA) (Yang, 1957; Chatham *et al.*, 1988) to inhibit all ATP-generating pathways. Following BTB treatment, the level of ATP was significantly preserved compared with the untreated cells (Figure 2B; $P < 0.001$), consistent with the BTB-mediated inhibition of the F₁F_o-ATPase. This evidence matches the data obtained from HL-1 cells and indicates a selectivity of BTB in conditions of impaired mitochondrial respiration.

Figure 2C shows an average trace for the $\Delta\Psi_m$ dissipation after BTB addition to cells bathed in NaCN. The kinetics of $\Delta\Psi_m$ dissipation were very similar to that recorded in HeLa cells overexpressing IF₁ in the same conditions of respiratory inhibition (Campanella *et al.*, 2008).

BTB protects against ischaemic cell death

HL-1 cells were pretreated with BTB prior to a period of ischaemia, and cell death was assayed using PI staining. This analysis (Figure 2D) showed that cell death was reduced substantially by BTB (100 μ M) to a level equivalent to that seen with either CsA (Sharov *et al.*, 2007) or diazoxide (Wang *et al.*, 1999; Murata *et al.*, 2001).

Interaction between BTB and IF₁

To further understand the mechanism via which BTB achieves protection, we asked whether its action could involve a participation of IF₁. HL-1 cells were transfected with either the IF₁ construct to induce overexpression of IF₁ or the IF₁ siRNA to silence this protein, in conjunction with CFP or YFP. Immunofluorescence experiments revealed a significant overexpression or silencing of IF₁ (Figure 2E and F).

After manipulating IF₁ expression, HL-1 cells were therefore monitored for the changes in $\Delta\Psi_m$ in conditions in which the F₁F_o-ATPase was forced to act in reverse (i.e. after inhibition of the ETC by rotenone and antimycin A). In these, when BTB was present, we observed a significant additional decrease in the SD/mean ratio in the +IF₁ cells compared with the non-transfected cells and a significantly lower decrease in this ratio in cells devoid of IF₁ (Figure 2G).

Such variations are therefore likely to depend on the level of IF₁ expression, thus suggesting a role for IF₁ in the action of BTB. Confirmation of this was given by the correlation with cell survival in HeLa cells (Figure 2H), as cell death following ischaemia was significantly higher in -IF₁ cells and lower in +IF₁ cells when treated with BTB as shown in Supporting Information Figure S1d.

The BTB-mediated protection was tested further in neurons. Primary cultured cortical neurons of mice were exposed to OGD, treated or not with BTB, followed by RX. The resulting cell death was significantly reduced by BTB, as scored by PI staining, compared with cells left untreated during OGD (Figure 3A and B)

These data imply a synergy between BTB and IF₁ as (i) modulation of $\Delta\Psi_m$ and (ii) protection from ischaemia are lost

when IF₁ is down-regulated. Ruling out that (i) BTB promotes any aberration of the mitochondrial network morphology (Figure 4A; $n = 6$) or (ii) matrix pH change (Supporting Information Figure S1e), which would predispose the activation of IF₁, we investigated the ratio of expression between the dimeric and tetrameric conformations of the protein in order to gain further insight into the mechanism of action.

BTB modifies the ratio of IF₁ dimers/tetramers

IF₁ is found in two conformations: dimeric or tetrameric, corresponding respectively to the active and inactive forms of the protein (Cabezon *et al.*, 2000). Dimers of IF₁ are found when mitochondrial respiration is inhibited as the conformation that binds the F₁ complex of the F₁F_o-ATPase. We therefore ran a Western blot analysis of HeLa cell protein extracts incubated with BTB both with and without inhibition of cellular respiration by addition of NaCN and IAA.

Exposure to BTB reduced the dimerization of IF₁ both under resting conditions and following addition of NaCN/IAA, while it increased the relative amount of the tetrameric form (Figure 4B, quantified in 4C). These data suggest that BTB promotes a shift of IF₁ conformation towards the tetrameric form, without altering the ability to dimerize during reversal of the F₁F_o-ATPase.

BTB rescues anaemia in pinotage zebrafish

A recent study surprisingly revealed that a zebrafish mutant, 'pinotage' (*pnt*) that is profoundly deficient in haemoglobin, is caused by a loss-of-function mutation in the *Atpif1a* gene, one of two *Atpif1* homologues found in the zebrafish (Figure 5A) (Shah *et al.*, 2012). The mechanism appears to involve mitochondrial iron overloading that impairs the enzyme ferrochelatase (Fech), with consequent inhibition of haemoglobin synthesis. We therefore explored whether BTB could rescue this phenotype by promoting the activity of the remaining IF₁ isoform, *Atpif1b*. This was carried out by incubating *pnt* zebrafish and control siblings with BTB (1 μ M) for 24 h. Remarkably, exposure to BTB rescued the anaemic phenotype of *pnt* (Figure 5B and C) with a significant increase in haemoglobin synthesis, as measured by positive staining with o-dianisidine.

Using TMRM, we measured $\Delta\Psi_m$ in *pnt* and control siblings to assess whether this response was related to altered mitochondrial bioenergetics. Measurement of TMRM accumulation in the olfactory bulbs (see images at different magnification in Figure 5D) showed that $\Delta\Psi_m$ was significantly increased in the *pnt* fish compared with controls, and was reduced to control levels following short-term treatment with BTB (Figure 5E). Treatment with vehicle, DMSO, alone had no effect (normalized fluorescence values normalized to sibling + DMSO: 1.08 ± 0.11 , *pnt* + DMSO: 1.46 ± 0.15 , $n = 4$ days of analysis). These data indicate that concentrations of BTB that restore haemoglobin biosynthesis also alter mitochondrial bioenergetics in living fish (Shah *et al.*, 2012).

Discussion and conclusions

The data presented here demonstrate that we have identified a drug candidate, BTB, which selectively inhibits the reversal




Figure 2

BTB spares mitochondrial ATP consumption and protects from ischaemic cell death in an IF₁-dependent fashion. (A) Indirect assessment of ATP intracellular levels through monitoring of MgG fluorescence in HL-1 cells in conditions when the F₁Fo-ATPsynthase is reversed using fluorescence microscopy. The bars show the change of MgG mean fluorescence 12 min after subsequent addition of BTB or oligomycin B following reversal of the enzyme by rotenone and antimycin A. The inhibitors of the ETC caused an increase in the MgG fluorescence (control), suggesting a decrease in intracellular (ATP) and thus a reversal of the F₁Fo-ATPsynthase. BTB and oligomycin significantly reduced this increase in fluorescence, suggesting preservation of ATP through inhibition of the reversed F₁Fo-ATPsynthase. Control, $n = 26$; oligomycin B, $n = 30$; BTB 100 μM , $n = 29$. $^{**}P < 0.001$, significantly different from control. (B) Time course of MgG fluorescence in HeLa cells with and without BTB following inhibition of respiration. At 80 min of NaCN and IAA treatment, $n = 8$. $^{**}P < 0.001$, $^{*}P < 0.05$, significant effects of BTB. (C) Kinetics of $\Delta\Psi_m$ dissipation in HeLa cells. TMRM fluorescence values are normalized to the initial baseline; mean data are shown from 3 experiments. (D) Protective effect of BTB against ischaemia/reperfusion in HL-1 cells: compared with the ischaemic control, BTB significantly reduced the cell death ratio after simulated ischaemia/reperfusion, as assessed by the ratio of PI-positive cells over Hoechst-positive cells, similarly to the positive controls of cardioprotection using CsA and diazoxide. Sham control, $n = 5$; CsA 200 nM, $n = 16$; diazoxide 100 μM , $n = 12$; BTB 100 μM , $n = 5$. $^{**}P < 0.001$, significantly different as shown. (E) Immunofluorescence assay confirming an efficient IF₁ overexpression or silencing. (F) Quantification of the efficiency of modulation of IF₁ in HL-1 cells. $n = 5$; $^{**}P < 0.001$, significantly different from control. (G) Effect of the modulation of IF₁ expression on the efficiency of BTB in conditions of reversion of the F₁Fo-ATPsynthase in HL-1 cells loaded with Rh123 using fluorescence microscopy. The $\Delta\Psi_m$ was monitored using the SD/mean fluorescence ratio. Similarly to Figure 1E, the bars show the change in $\Delta\Psi_m$ 15 min after the addition of BTB when the F₁Fo-ATPsynthase was reversed by rotenone and antimycin A. Addition of BTB in +IF₁ cells resulted in a potentiation of its effect on $\Delta\Psi_m$ (mitochondrial depolarization) compared with non-transfected HL-1 cells, suggesting that overexpression of IF₁ potentiated the effect of BTB while silencing of IF₁ (-IF₁) reduced its effect. $n = 112$; $^{**}P < 0.001$, significantly different from control. (H) Histogram of BTB-mediated protection in HeLa cells from ischaemic cell death, scored by PI staining. $^{**}P < 0.001$, significantly different from control.

of the F₁Fo-ATPsynthase. This is a deleterious activity causing ATP wastage and represents a key factor contributing to ischaemic cell death, which is still the major cause of death in Western countries (McGovern *et al.*, 1996; Dudas *et al.*, 2011; Roger *et al.*, 2012). BTB preserves ATP in ischaemia-like experimental protocols inhibiting the F₁Fo-ATPase via a synergy with IF₁ (Faccenda and Campanella, 2012).

A molecule consistent with previous findings

These results support the earlier work on BMS199264 (Grover *et al.*, 2004), the compound on which we based our search for BTB. Grover *et al.* (2004) demonstrated, with sub-mitochondrial particles that BMS199264 was selective against the hydrolase activity of the F₁Fo-ATPsynthase, as opposed to its synthase activity (Atwal *et al.*, 2004). The question is how any low MW inhibitor might selectively act on only one direction of enzymic action. Our data suggest that this is feasible if the drug operates through potentiating the action of the endogenous inhibitor IF₁. By showing changes in the efficacy of BTB in cells in which the expression of IF₁ has been up- and down-regulated, we have shown that BTB efficacy depends on IF₁ expression. It would be interesting to know whether this is also true of BMS199264, which we have been unable to obtain. Our findings also have the interesting corollary that the effects of BTB may vary in different tissues dependent on the expression level of IF₁, which we have shown previously to vary significantly between different cell types (Campanella *et al.*, 2008).

The physiological implications

If we consider myocardial ischaemia, the heart being the first tissue in which IF₁ was discovered and probably one of the richest sources of this protein, our data suggests BTB is an interesting candidate to prevent cellular damage following myocardial ischaemia (Pullman and Monroy, 1963). The same considerations would apply to neurons in which the IF₁

level is particularly high (Campanella *et al.*, 2008), and also proximal tubules of the kidney (Hall *et al.*, 2009). The data we present here in primary cultures of neurons sustain this hypothesis. On the same principles, the potential effects of BTB in neoplastic pathologies that show IF₁ enrichment and resistance to chemotherapy-induced cell death (Luciakova and Kuzela, 1984; Yamada and Huzel, 1992; Capuano *et al.*, 1997; Faccenda *et al.*, 2013) could be explored.

The role of the F₁Fo-ATPsynthase acting as an F₁Fo-ATPase, hence consuming ATP, in ischaemia-induced cell death still remains controversial. The work of Chinopoulos *et al.* (2010; Chinopoulos, 2011) suggests that the ATP synthase and the adenine nucleotide translocase (ANT) do not share the same 'reversal potential', meaning that the mitochondrial F₁Fo-ATPsynthase could work in reverse mode with the ANT working in the forward one. This would result in the F₁Fo-ATPase hydrolysing the ATP stocks in the mitochondria but without any supply of cytosolic ATP through the ANT, and thus without any significant effect on the cytosolic ATP supplies which would be maintained by glycolytic activity. There is no doubt, however, that there is a decrease in total cellular ATP during ischaemia, which can be preserved both by oligomycin and by BTB, arguing strongly that ATP hydrolysis is indeed driven by the F₁Fo-ATPsynthase in reverse.

The molecular implications beyond the F₁Fo-ATPsynthase

The BTB-mediated protection from ischaemia could imply an effect on the formation of mPTPs, which was very recently associated with the F₁Fo-ATPsynthase (Giorgio *et al.*, 2013). We have no data to suggest that BTB inhibits mPTP opening. We have also seen before that inhibition of the F₁Fo-ATPase by oligomycin did not prevent opening of the mPTP in a cardiomyocyte cell model, although it did radically slow the rate of ATP depletion (Duchen, 2000). Notably, BTB has a chemical structure different from that of any known existing




Figure 3

BTB prevention of neuronal cell death following treatment with OGD/RX. (A) Cortical neurons were exposed to OGD/RX (3 h OGD+24 h RX) with or without 100 μ M BTB and stained for FDA and PI. (B) Summary data from PI-stained neurons, shown as % total number of neurons. $n = 2$; ** $P < 0.001$, * $P < 0.05$, significantly different as shown.

mPTP modulators, which would suggest that a direct regulatory effect could be excluded.

Rescuing haemoglobin synthesis in pinotage

The data from the *pnt* zebrafish imply that BTB is absorbed in the fish *in vivo* without causing significant toxicity and sustain the hypothesis that it might compensate pharmacologically for the deficiencies of IF $_1$ expression. The defect in haemoglobin synthesis described in *pnt* is a consequence of impaired mitochondrial bioenergetics, resulting from a loss

of Atpif1a that leads to mitochondrial iron (Fe $^{2+}$) accumulation of ferrochelatase, the terminal enzyme in haem biosynthesis (Shah *et al.*, 2012). Long-term treatment with BTB-restored haemoglobin synthesis in a large portion of the *pnt* zebrafish population, attributable to an action on mitochondrial bioenergetics as the $\Delta\Psi_m$, which was elevated in the untreated *pnt* mutant, was normalized following exposure to BTB.

In conclusion, our data suggest that BTB is an interesting potential candidate to reduce ischaemia-induced cellular




Figure 4

Mitochondrial network morphology in BTB-treated cells and IF₁ dimers/tetramers ratio. (A) Mitochondrial network morphology in HeLa cells analysed via MitoTracker Green. (B) Immunoblotting of IF₁ dimers and tetramers in control and ischaemic conditions with and without BTB treatment. (C) Quantification of IF₁ dimers/tetramers ratio. $n = 4$; $*P < 0.05$, significantly different as shown.

injury, without impairing ATP generation under resting conditions and without evident *in vivo* toxicity, at least in the zebrafish. This compound specifically targets the reversal of the F₁Fo-ATP synthase, which, to the best of our knowledge, remains untargeted. The data help to establish an important proof of principle to suggest that the selective inhibition of the ATPase function of the F₁Fo-ATP synthase may represent a viable therapeutic approach to conditions in which mitochondrial respiration is impaired.

Acknowledgements

We are grateful to Professor G Churchill, Dr S Vasudevan and Professor A Ganesan for advising with the use of the cheminformatics screening for BTB <http://zinc.docking.org>. A BBSRC Research Placement supported A. A. A. at the time of the experiments. A grant from the Federation Française de Cardiologie supported F. I. at the time of experiments. The research activities led by M. C. are supported by the BBSRC




Figure 5

BTB-mediated rescue of haemoglobin synthesis in *pnt* zebrafish embryos. (A) Representative images of 3 dpf larvae from sibling and heterozygous *pnt* cross showing how anaemia is identified. (B) Detection of haemoglobin biosynthesis in *pnt* embryos, untreated and treated with BTB, using o-dianisidine staining. (C) Summary data of the *pnt* phenotype rescue by BTB, as illustrated in (B). Data are shown as percentage of total *pnt* population staining positively; $n = 18$; $*P < 0.05$. (D) Sample confocal images for the mitochondrial membrane potential ($\Delta\Psi_m$) measured with TMRM in the olfactory bulbs in living zebrafish embryos with detailed screenshot of mitochondria. (E) Summary data of TMRM values of $\Delta\Psi_m$ in single mitochondria of *wt* and *pnt* embryos without and with BTB. Fluorescence intensity values are normalized to control; $n = 4$ days of analysis. $**P < 0.001$, $*P < 0.05$, significantly different as shown.

New Investigator Award Grant (BB/I013695/1), PPCT, Central Research Fund of the University of London, Local Funds of the Royal Veterinary College, EBRI-Rita Levi Montalcini Foundation Research Programme in Metabolism in Brain Diseases and LAM Research Grant on Brain Tumours. C. R. and

C. H. K. C. (a BSc Project student) were supported by local funds of the Royal Veterinary College. E. A. was supported by University College London as an Intercalated BSc Project student located at the Royal Veterinary College supervised by M. C. and C. R.

Conflict of interest

None.

References

- Atwal KS, Wang P, Rogers WL, Sleph P, Monshizadegan H, Ferrara FN *et al.* (2004). Small molecule mitochondrial F₁F₀ ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors. *J Med Chem* 47: 1081–1084.
- Cabezón E, Butler PJ, Runswick MJ, Walker JE (2000). Modulation of the oligomerization state of the bovine F₁-ATPase inhibitor protein, IF₁, by pH. *J Biol Chem* 275: 25460–25464.
- Cabezón E, Runswick MJ, Leslie AG, Walker JE (2001). The structure of bovine IF(1), the regulatory subunit of mitochondrial F-ATPase. *EMBO J* 20: 6990–6996.
- Campanella M, Casswell E, Chong S, Farah Z, Wieckowski MR, Abramov AY *et al.* (2008). Regulation of mitochondrial structure and function by the F₁F₀-ATPase inhibitor protein, IF₁. *Cell Metab* 8: 13–25.
- Capuano F, Guerrieri F, Papa S (1997). Oxidative phosphorylation enzymes in normal and neoplastic cell growth. *J Bioenerg Biomembr* 29: 379–384.
- Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C (2007). Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. *Epilepsia* 48: 654–662.
- Chatham J, Gilbert HF, Radda GK (1988). Inhibition of glucose phosphorylation by fatty acids in the perfused rat heart. *FEBS Lett* 238: 445–449.
- Chinopoulos C (2011). Mitochondrial consumption of cytosolic ATP: not so fast. *FEBS Lett* 585: 1255–1259.
- Chinopoulos C, Gerencsér AA, Mandi M, Mathe K, Torocsik B, Doczi J *et al.* (2010). Forward operation of adenine nucleotide translocase during F₀F₁-ATPase reversal: critical role of matrix substrate-level phosphorylation. *FASEB J* 24: 2405–2416.
- Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A *et al.* (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. *Proc Natl Acad Sci U S A* 95: 2979–2984.
- Duchen MR (2000). Mitochondria and Ca²⁺ in cell physiology and pathophysiology. *Cell Calcium* 28: 339–348.
- Duchen MR, Surin A, Jacobson J (2003). Imaging mitochondrial function in intact cells. *Methods Enzymol* 361: 353–389.
- Dudas K, Lappas G, Stewart S, Rosengren A (2011). Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). *Circulation* 123: 46–52.
- Dugan LL, Bruno VM, Amagasa SM, Giffard RG (1995). Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. *J Neurosci* 15: 4545–4555.
- Faccenda D, Campanella M (2012). Molecular regulation of the mitochondrial F(1)F(0)-ATP synthase: physiological and pathological significance of the inhibitory factor 1 (IF(1)). *Int J Cell Biol* 2012: 367934.
- Faccenda D, Tan CH, Seraphim A, Duchén MR, Campanella M (2013). IF₁ limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. *Cell Death Differ* 20: 686–697.
- Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M *et al.* (2013). Dimers of mitochondrial ATP synthase form the permeability transition pore. *Proc Natl Acad Sci U S A* 110: 5887–5892.
- Goldberg MP, Choi DW (1993). Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. *J Neurosci* 13: 3510–3524.
- Green DW, Grover GJ (2000). The IF(1) inhibitor protein of the mitochondrial F(1)F(0)-ATPase. *Biochim Biophys Acta* 1458: 343–355.
- Grover GJ, Atwal KS, Sleph PG, Wang FL, Monshizadegan H, Monticello T *et al.* (2004). Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F₁F₀-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity. *Am J Physiol Heart Circ Physiol* 287: H1747–H1755.
- Hall AM, Unwin RJ, Parker N, Duchén MR (2009). Multiphoton imaging reveals differences in mitochondrial function between nephron segments. *J Am Soc Nephrol* 20: 1293–1302.
- Harris DA, Das AM (1991). Control of mitochondrial ATP synthesis in the heart. *Biochem J* 280 (Pt 3): 561–573.
- Irwin JJ, Shoichet BK (2005). ZINC – a free database of commercially available compounds for virtual screening. *J Chem Inf Model* 45: 177–182.
- Jennings RB, Reimer KA, Steenbergen C (1991). Effect of inhibition of the mitochondrial ATPase on net myocardial ATP in total ischemia. *J Mol Cell Cardiol* 23: 1383–1395.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting *in vivo* experiments: the ARRIVE guidelines. *Br J Pharmacol* 160: 1577–1579.
- Leyssens A, Nowicky AV, Patterson L, Crompton M, Duchén MR (1996). The relationship between mitochondrial state, ATP hydrolysis, [Mg²⁺]_i and [Ca²⁺]_i studied in isolated rat cardiomyocytes. *J Physiol* 496 (Pt 1): 111–128.
- Luciakova K, Kuzela S (1984). Increased content of natural ATPase inhibitor in tumor mitochondria. *FEBS Lett* 177: 85–88.
- Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B (1962). A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. *J Clin Invest* 41: 1776–1804.
- Manev H, Favaron M, Vicini S, Guidotti A, Costa E (1990). Glutamate-induced neuronal death in primary cultures of cerebellar granule cells: protection by synthetic derivatives of endogenous sphingolipids. *J Pharmacol Exp Ther* 252: 419–427.
- Matsuno-Yagi A, Hatefi Y (1993). Studies on the mechanism of oxidative phosphorylation. Different effects of F₀ inhibitors on unisite and multisite ATP hydrolysis by bovine submitochondrial particles. *J Biol Chem* 268: 1539–1545.
- McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H *et al.* (1996). Recent trends in acute coronary heart disease – mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. *N Engl J Med* 334: 884–890.
- McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. *Br J Pharmacol* 160: 1573–1576.
- Murata M, Akao M, O'Rourke B, Marban E (2001). Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload

during simulated ischemia and reperfusion: possible mechanism of cardioprotection. *Circ Res* 89: 891–898.

Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A *et al.* (2009). Identification of a chemical probe for NAADP by virtual screening. *Nat Chem Biol* 5: 220–226.

Paffett-Lugassy NN, Zon LI (2005). Analysis of hematopoietic development in the zebrafish. *Methods Mol Med* 105: 171–198.

Papadimitriou C, Yapijakis C, Davaki P (2004). Use of truncated pyramid representation methodology in three-dimensional reconstruction: an example. *J Microsc* 214 (Pt 1): 70–75.

Power J, Cross RL, Harris DA (1983). Interaction of F₁-ATPase, from ox heart mitochondria with its naturally occurring inhibitor protein. Studies using radio-iodinated inhibitor protein. *Biochim Biophys Acta* 724: 128–141.

Pullman ME, Monroy GC (1963). A naturally occurring inhibitor of mitochondrial adenosine triphosphatase. *J Biol Chem* 238: 3762–3769.

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB *et al.* (2012). Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. *Circulation* 125: e2–e220.

Rosen D, Lewis AM, Mizote A, Thomas JM, Aley PK, Vasudevan SR *et al.* (2009). Analogues of the nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist Ned-19 indicate two binding sites on the NAADP receptor. *J Biol Chem* 284: 34930–34934.

Rouslin W (1991). Regulation of the mitochondrial ATPase *in situ* in cardiac muscle: role of the inhibitor subunit. *J Bioenerg Biomembr* 23: 873–888.

Rouslin W, Erickson JL, Solaro RJ (1986). Effects of oligomycin and acidosis on rates of ATP depletion in ischemic heart muscle. *Am J Physiol* 250 (3 Pt 2): H503–H508.

Rouslin W, Broge CW, Grupp IL (1990). ATP depletion and mitochondrial functional loss during ischemia in slow and fast heart-rate hearts. *Am J Physiol* 259 (6 Pt 2): H1759–H1766.

Rouslin W, Frank GD, Broge CW (1995). Content and binding characteristics of the mitochondrial ATPase inhibitor, IF₁, in the tissues of several slow and fast heart-rate homeothermic species and in two poikilotherms. *J Bioenerg Biomembr* 27: 117–125.

Savoia C, Sisalli MJ, Di Renzo G, Annunziato L, Scorziello A (2011). Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. *Int J Physiol Pathophysiol Pharmacol* 3: 57–64.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T *et al.* (2012). Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9: 676–682.

Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL *et al.* (2012). Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. *Nature* 491 (7425): 608–612.

Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN (2007). Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. *J Mol Cell Cardiol* 42: 150–158.

Vinogradov AD (2000). Steady-state and pre-steady-state kinetics of the mitochondrial F₁F₀ ATPase: is ATP synthase a reversible molecular machine? *J Exp Biol* 203 (Pt 1): 41–49.

Wang Y, Hirai K, Ashraf M (1999). Activation of mitochondrial ATP-sensitive K(+) channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. *Circ Res* 85: 731–741.

Westerfield M (2007). *The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)*, 5th edn. Univ. of Oregon Press: Eugene.

Yamada EW, Huzel NJ (1992). Distribution of the ATPase inhibitor proteins of mitochondria in mammalian tissues including fibroblasts from a patient with Luft's disease. *Biochim Biophys Acta* 1139: 143–147.

Yang WC (1957). Effect of iodoacetate and iodoacetamide on oxygen uptake of heart mitochondria. *Science* 125 (3257): 1087.

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

<http://dx.doi.org/10.1111/bph.12638>

Figure S1 Ribbon modelling of the BTB binding to the F₁F₀-ATP synthase mitochondrial membrane potential ($\Delta\Psi_m$) and cell death images. (a) Ribbon model and (b) link to animated ribbon modelling of the BTB binding to the β -subunit of the F₁F₀-ATP synthase. (c) Kinetics of $\Delta\Psi_m$ modulation in HeLa during exposure, respectively, to BTB and oligomycin. (d) Images of HeLa cells positive and not, to PI undergoing ischaemic treatment in the presence/absence of BTB with and without IF₁ expression. (e) Mitochondrial pH data in DMSO and BTB-treated HeLa Cells.